Evaluation of Losartan to Prevent Stiffness Following Total Knee Replacement Surgery

What this Trial Is About

Researchers are evaluating the use of Losartan after total knee arthroplasty TKA to see if it can reduce or prevent arthrofibrosis, a condition that limits knee movement and affects clinical outcomes. This double-blind, randomized, placebo-controlled trial aims to assess the efficacy and safety of Losartan in improving patient-reported outcomes and reducing fibrosis, which will be measured by knee range of motion and thickness of the knee capsule. Participants will be randomly assigned to receive either Losartan 12.5 mg or a matching placebo twice daily for four weeks, starting the day after their knee replacement surgery. The study involves 120 patients undergoing primary TKA and includes two groups one taking Losartan and one taking placebo, both for the same duration and dosage. During the study, participants will undergo assessments at baseline, 6 weeks, and 3 months after surgery. These include ultrasound measurements of knee capsule thickness, knee range of motion, blood tests for immune and growth factor markers, strength testing, and patient questionnaires about pain and health status. Safety will be monitored throughout the study, which lasts approximately 3.5 months from the start of dosing.

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan